Guardant Health (NASDAQ:GH) Issues Earnings Results

Guardant Health (NASDAQ:GH) announced its quarterly earnings results on Thursday. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.02, FiscalAI reports. The firm had revenue of $301.67 million for the quarter, compared to analyst estimates of $279.15 million. The business’s revenue was up 48.3% compared to the same quarter last year. During the same period last year, the firm posted ($0.49) EPS.

Here are the key takeaways from Guardant Health’s conference call:

• Q1 beat and higher full‑year guide — Guardant reported $302M in Q1 revenue (+48% YoY), surpassed $1B TTM revenue, and raised 2026 guidance to $1.30B–$1.32B, signaling sustained top‑line momentum.
• Shield screening momentum and margin expansion — Shield generated $42M on ~44k tests in Q1, with >90% adherence, nationwide Quest distribution, a new 2‑tube FDA kit approval, Asia rollout with Manulife, and screening gross margin improvement from 18% to 56%; 2026 Shield guidance is $186M–$198M (~230k–245k tests).
• Oncology product and AI platform traction — Oncology revenue was $205M (+36%); Guardant360 Liquid volumes +30%, Guardant360 Tissue accelerating after whole‑transcriptome upgrade, and Reveal volumes >100% as InfinityAI/SmartApps drive deeper adoption; Guardant360 Liquid remains in FDA review.
• Biopharma/data partnerships and CDx momentum — Biopharma & data revenue was $53M (+17%), Guardant now supports 26 CDx approvals across regions, and strategic deals (e.g., Merck, Nuvalent) plus InfinityAI real‑world evidence are strengthening long‑term commercial pipelines.
• Higher operating spend and ongoing cash burn — Non‑GAAP operating expenses rose 34% to $268M (S&M growth), adjusted EBITDA loss remained $59M, Q1 free cash flow burn was $71M and full‑year FCF burn is guided to $185M–$195M; the company has ~$1.2B cash but continues to reinvest heavily, which may pressure near‑term profitability.

Guardant Health Price Performance

Shares of Guardant Health stock traded up $0.01 during trading on Thursday, hitting $92.26. The stock had a trading volume of 2,389,102 shares, compared to its average volume of 2,172,853. The business has a fifty day moving average of $88.93 and a two-hundred day moving average of $96.92. Guardant Health has a fifty-two week low of $36.36 and a fifty-two week high of $120.74. The firm has a market cap of $12.23 billion, a P/E ratio of -27.87 and a beta of 1.48.

Insider Buying and Selling at Guardant Health

In other news, Director Medina Manuel Hidalgo sold 1,300 shares of the firm’s stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $91.54, for a total transaction of $119,002.00. Following the completion of the transaction, the director owned 1,193 shares in the company, valued at approximately $109,207.22. This trade represents a 52.15% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Musa Tariq sold 348 shares of the firm’s stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $88.09, for a total transaction of $30,655.32. Following the sale, the director owned 8,394 shares of the company’s stock, valued at $739,427.46. The trade was a 3.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 8,596 shares of company stock valued at $775,767 in the last ninety days. 6.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Guardant Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Parallel Advisors LLC boosted its position in shares of Guardant Health by 164.7% in the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after buying an additional 219 shares during the period. EFG International AG acquired a new stake in shares of Guardant Health during the fourth quarter worth approximately $41,000. Kestra Advisory Services LLC acquired a new position in Guardant Health in the 4th quarter valued at approximately $56,000. Itau Unibanco Holding S.A. acquired a new stake in shares of Guardant Health during the 4th quarter valued at $60,000. Finally, Arax Advisory Partners increased its stake in shares of Guardant Health by 61.5% in the fourth quarter. Arax Advisory Partners now owns 733 shares of the company’s stock worth $75,000 after acquiring an additional 279 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on GH. BTIG Research boosted their target price on shares of Guardant Health from $140.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, February 20th. JPMorgan Chase & Co. boosted their price objective on Guardant Health from $120.00 to $130.00 and gave the stock an “overweight” rating in a research report on Friday, February 20th. TD Cowen raised their target price on Guardant Health from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Friday, February 20th. Evercore set a $110.00 price target on Guardant Health in a research report on Friday, February 20th. Finally, Raymond James Financial reissued an “outperform” rating and issued a $129.00 price target on shares of Guardant Health in a research note on Monday, February 23rd. Nineteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $128.63.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.